1Wetmore JB,Quades LD.Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease:time for a paradigm shift? Nat Clin Pract Nephrol,2009,5:24-33.
3Kuro-o M.Klotho in chronic kidney disease--what' s new?Nephrol Dial Transplant,2009,24(6):1705-1708.
4Ketteler M,Biggar PH.As nature did not predict dialysis-what we can learn from FGF23 in end-stage renal disease? Nephrol Dial Transplant,2009,24(9):2618-2620.
5Martin KI,Goldfarb S.Renal bone disease,disorders of divalent ions and nephrolithiasis NephSAP,2008,7:304-317.
6Valle C,Rodriguez M,Santarnaria R,et al.Cinacalcet reduces the set point of the PTH-calcium curve.J Am Soc Nephrol,2008,19(12):2430-2436.
7Messa P,Macário F,Yaqoob M,et al.The OPTIMA study:assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.Clin J Am Soc Nephrol,2008,3(1):36-45.
8Fishbane S,Shapiro WB,Corry DB,et al.Cinacalcet HCI and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidisrn in dialysis patients compared with vitamin D alone:the ACHIEVE study results.Clin J Am Soc Nephrol,2008,3(6):1718-1725.
9Strippoli GF,Palmer S,Tong A,et al.Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.Am J Kidney Dis,2006,47(5):715-726.
10Sprague SM,Evenepoel P,Curzi MP,et al.Simultaneous control of PTH and Ca×P Is sustained over three years of treatment with cinacalcet HC1.Clin J Am Soc Nephrol,2009,4(9):1465-1476.
